Related Experiment Video
Updated: Jan 9, 2026
Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
Published on: March 3, 2023
Biologic outcomes in patients with severe asthma and clinically relevant allergy in the CHRONICLE study
Bradley E Chipps1, Warner W Carr2, Reynold A Panettieri3
1Capital Allergy & Respiratory Disease Center, Sacramento, Calif.
Background:
Several mAb biologic therapies are approved for the treatment of severe asthma. There are limited data examining biologic outcomes in patients with allergy that has been clinically confirmed to exacerbate their asthma symptoms.
Objective:
Our aim was to assess rates of asthma exacerbations, exacerbation-related emergency department (ED) visits, and exacerbation-related hospitalizations before and after biologic initiation among adults with severe asthma and confirmed clinically relevant allergy.
Methods:
CHRONICLE was an observational study of subspecialist-treated US adults with severe asthma. Annualized rates of asthma exacerbations, exacerbation-related ED visits, and exacerbation-related hospitalizations (6 months before and after initiation of biologic treatment) were compared for patients who had clinician-confirmed clinically relevant allergy and regular exposure to relevant asthma-exacerbating allergens and were enrolled between February 2018 and February 2024.
Results:
Overall, 214 patients with confirmed allergy and regular allergen exposure were analyzed (67% were female and 76% were White; the mean age at enrollment was 53 years). After initiation of biologics, the rates of asthma exacerbations, exacerbation-related ED visits, and exacerbation-related hospitalizations decreased by 61% (decreasing from 1.49 to 0.58 per patient year [P < .0001]), 55% (decreasing from 0.29 to 0.13 per patient year [P = .0032]), and 75% (decreasing from 0.16 to 0.04 per patient year [P = .0008]), respectively. The reductions in exacerbation rates trended higher in patients using anti-IL-4 receptor/anti-thymic stromal lymphopoietin biologics (73% [P <.0001]) than in patients using anti-IgE (57% [P = .0376]) and anti-IL-5/IL-5 receptor (55% [P < .0001]) biologics.
Conclusion:
Among this cohort of US subspecialist-treated adults with severe asthma and clinically relevant allergy, biologics decreased the rates of exacerbations, exacerbation-related ED visits, and exacerbation-related hospitalizations, regardless of biologic subgroup.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:24Asthma-III: Symptoms and Complications
Classification of Asthma
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...